Amedisys (AMED) Competitors

Amedisys (NASDAQ:AMED) and DaVita (NYSE:DVA) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.

Do analysts recommend AMED or DVA?

Amedisys currently has a consensus target price of $100.75, suggesting a potential upside of 3.38%. DaVita has a consensus target price of $164.50, suggesting a potential upside of 16.56%. Given DaVita's higher possible upside, analysts plainly believe DaVita is more favorable than Amedisys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amedisys	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25
DaVita	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Is AMED or DVA more profitable?

DaVita has a net margin of 6.63% compared to Amedisys' net margin of 3.79%. DaVita's return on equity of 176.11% beat Amedisys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amedisys	3.79%	12.52%	7.01%
DaVita	6.63%	176.11%	4.66%

Do institutionals and insiders hold more shares of AMED or DVA?

94.4% of Amedisys shares are held by institutional investors. Comparatively, 90.1% of DaVita shares are held by institutional investors. 2.1% of Amedisys shares are held by company insiders. Comparatively, 2.0% of DaVita shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Which has better earnings and valuation, AMED or DVA?

DaVita has higher revenue and earnings than Amedisys. DaVita is trading at a lower price-to-earnings ratio than Amedisys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amedisys	$2.35B	1.36	$43.23M	$2.71	35.96
DaVita	$12.82B	0.83	$936.34M	$10.09	13.99

Does the media prefer AMED or DVA?

In the previous week, DaVita had 8 more articles in the media than Amedisys. MarketBeat recorded 13 mentions for DaVita and 5 mentions for Amedisys. DaVita's average media sentiment score of 1.18 beat Amedisys' score of 1.12 indicating that DaVita is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amedisys	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DaVita	9 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility and risk, AMED or DVA?

Amedisys has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500. Comparatively, DaVita has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500.

Summary

DaVita beats Amedisys on 9 of the 15 factors compared between the two stocks.